NCT00630149View on ClinicalTrials.gov

Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2011

Study Completion Date

January 31, 2012

Conditions
Nasopharyngeal Neoplasms
Interventions
DRUG

Pemetrexed (Alimta)

500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.

Trial Locations (1)

510000

Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Sun Yat-sen University

OTHER

NCT00630149 - Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy | Biotech Hunter | Biotech Hunter